Key Takeaways
- • The top 30 pharmaceutical companies have a combined market capitalization of roughly $5 trillion, putting the sector on a scale comparable to major software businesses, according to an Andreessen Horowitz report published November 13, 2026.
- • Nine publicly traded pharma companies are valued above $200 billion, versus 16 publicly traded software companies that exceed the same threshold.
- • Eli Lilly's market capitalization exceeds $1 trillion, with its GLP-1 portfolio generating close to $17 billion in revenue in Q3 2026, nearly matching Anthropic's revenue for that quarter.
- • Lilly's GLP-1 portfolio accounted for 63% of its 2025 revenue, and the top 10 pharma companies derive roughly 50% of revenue from their three leading assets.
- • Drug patents provide 20 years of exclusivity from filing, typically leaving 10-14 years of commercial exclusivity after launch, with sales peaking an average of six years after launch.
Summary
The top 30 pharmaceutical companies have a combined market capitalization of roughly $5 trillion, according to a report titled "Big Pharma Can Rival Big Software" published on November 13, 2026 by Andreessen Horowitz. The report states that the sector now operates on a scale comparable to major software businesses. Nine publicly traded pharma companies are valued above $200 billion, while the report says 16 publicly traded software companies exceed the same threshold.
Eli Lilly is the report's central example of this scale. Its market capitalization exceeds $1 trillion, and the company joined this valuation bracket following the successful launch of tirzepatide, a key drug in the GLP-1+ class. According to the report, Lilly's GLP-1 portfolio generated close to $17 billion in revenue in the third quarter of 2026, nearly matching Anthropic's revenue for that quarter. The report cited analyst expectations that annual sales from the portfolio would exceed $100 billion by 2030. Lilly's injectable GLP-1 drugs, Mounjaro and Zepbound, generated nearly $40 billion in sales in 2025, roughly matching Salesforce's revenue over the same period.
Andreessen Horowitz characterized drug development as dependent on a small number of major successes, while approved drugs can provide recurring revenue for years. The top 10 pharmaceutical companies derive roughly 50% of revenue from their three leading assets. Lilly's GLP portfolio accounted for 63% of its revenue in 2025, illustrating how a handful of successful drugs can shape overall company results.
The report identifies patent protection as a foundation for sustained revenue. Drug patents are typically filed before clinical trials and provide 20 years of exclusivity from filing, leaving a typical commercial exclusivity period of 10-14 years after launch. Sales reach their peak an average of six years after commercial launch, allowing successful drugs to maintain market leadership for years under patent protection, the report said.
Eli Lilly is the report's central example of this scale. Its market capitalization exceeds $1 trillion, and the company joined this valuation bracket following the successful launch of tirzepatide, a key drug in the GLP-1+ class. According to the report, Lilly's GLP-1 portfolio generated close to $17 billion in revenue in the third quarter of 2026, nearly matching Anthropic's revenue for that quarter. The report cited analyst expectations that annual sales from the portfolio would exceed $100 billion by 2030. Lilly's injectable GLP-1 drugs, Mounjaro and Zepbound, generated nearly $40 billion in sales in 2025, roughly matching Salesforce's revenue over the same period.
Andreessen Horowitz characterized drug development as dependent on a small number of major successes, while approved drugs can provide recurring revenue for years. The top 10 pharmaceutical companies derive roughly 50% of revenue from their three leading assets. Lilly's GLP portfolio accounted for 63% of its revenue in 2025, illustrating how a handful of successful drugs can shape overall company results.
The report identifies patent protection as a foundation for sustained revenue. Drug patents are typically filed before clinical trials and provide 20 years of exclusivity from filing, leaving a typical commercial exclusivity period of 10-14 years after launch. Sales reach their peak an average of six years after commercial launch, allowing successful drugs to maintain market leadership for years under patent protection, the report said.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.